VEAT notice for the supply, installation, validation, interfacing, staff training and maintenance of Nova StatStrip® glucose/ketone meters for the POCT determination of blood glucose and β-hydroxybutyrate.

EF25Voluntary ex-ante transparency notice – general directive9626d4e6-c80f-4704-8388-f104655ae78aTHTallaght University Hospital
Estimated value—
Deadline—
Competition00 participants
Lots11 lot

Keep momentum on this opportunity

Save it on this device now. Create an account when you are ready to track deadlines, notes, and teamwork.

  • Save and reuse search filters
  • Track opportunities as pursuits
  • Get notified when new notices match
Quick actions

Keep this notice in a shortlist so you can return to it without starting a bid.

Keep notes, monitor deadlines and collaborate with your team. This does not submit a bid or contact the buyer.

Receive alerts

Key information

Contract type
—
Deadline
—
CPV codes
38000000 - Laboratory, optical and precision equipments (excl. glasses)
Status
Awarded
Notice type
EF25Voluntary ex-ante transparency notice – general directive
Source
Estimated value
—
Publication date
8 Sept 2026, 23:00

Overview

: The objective of this Voluntary Ex Ante Transparency (VEAT) notice is to inform the market of Tallaght University Hospital intention to enter into a contractual duration period with Nova Biomedical in accordance with Article 32.2(b) (i.e. the works, supplies or services can be provided only by a particular economic operator for any of the following reasons: (ii) competition is absent for technical reasons; (iii) the protection of exclusive rights, including property rights). For the supply, installation, validation, interfacing, staff training and maintenance of 146 handheld Nova StatStrip® dual functionality glucose/ketone meters for the POCT determination of approximately 261,000 blood glucose tests and 45,000 β-hydroxybutyrate tests per year. Supply of internal quality control sufficient for once- daily internal quality per meter. The meters will be fully interfaced to AQURE data management system for automatic upload of patient results, Operator ID, Device ID, QC results. The meter must have dual functionality suitable for the measurement of both blood β-hydroxybutyrate and glucose. It must be suitable for adult and paediatric clinical use and have a clinically appropriate measuring range for diagnosis and management of: Diabetic ketoacidosis (DKA) and ketosis. The meter must be CE-marked for in-vitro diagnostic (IVD) use (IVDR compliant where applicable) and compliant with relevant ISO standards (e.g. ISO 15197 or equivalent where applicable). The meter must be handheld, have dual glucose/ketone functionality be of robust design suitable for high-throughput clinical areas. It must have an easy-to-use interface with minimal training burden, barcode scanning or manual entry for patient/operator identification and clear display of results and flags for critical values. On-site or remote initial user training and super-user training must be provided along with provision of training materials (SOPs, IFUs, quick reference guides). Ongoing technical support and troubleshooting, defined service, maintenance, and warranty arrangements, assistance with middleware configuration and go-live support must also be provided. The hospital immediate requirement is for the provision of

The objective of this Voluntary Ex Ante Transparency (VEAT) notice is to inform the market of Tallaght University Hospital intention to enter into a contractual duration period with Nova Biomedical in accordance with Article 32.2(b) (i.e. the works, supplies or services can be provided only by a particular economic operator for any of the following reasons: (ii) competition is absent for technical reasons; (iii) the protection of exclusive rights, including property rights). For the supply, installation, validation, interfacing, staff training and maintenance of 146 handheld Nova StatStrip® dual functionality glucose/ketone meters for the POCT determination of approximately 261,000 blood glucose tests and 45,000 β-hydroxybutyrate tests per year. Supply of internal quality control sufficient for once- daily internal quality per meter. The meters will be fully interfaced to AQURE data management system for automatic upload of patient results, Operator ID, Device ID, QC results. The meter must have dual functionality suitable for the measurement of both blood β-hydroxybutyrate and glucose. It must be suitable for adult and paediatric clinical use and have a clinically appropriate measuring range for diagnosis and management of: Diabetic ketoacidosis (DKA) and ketosis. The meter must be CE-marked for in-vitro diagnostic (IVD) use (IVDR compliant where applicable) and compliant with relevant ISO standards (e.g. ISO 15197 or equivalent where applicable). The meter must be handheld, have dual glucose/ketone functionality be of robust design suitable for high-throughput clinical areas. It must have an easy-to-use interface with minimal training burden, barcode scanning or manual entry for patient/operator identification and clear display of results and flags for critical values. On-site or remote initial user training and super-user training must be provided along with provision of training materials (SOPs, IFUs, quick reference guides). Ongoing technical support and troubleshooting, defined service, maintenance, and warranty arrangements, assistance with middleware configuration and go-live support must also be provided. The hospital immediate requirement is for the provision of

Contracting authorities1

Lots1

Documentation1

1 document
  • VEAT notice for the supply, installation, validation, interfacing, staff training and maintenance of Nova StatStrip® glucose_ketone meters for the POCT determination of blood glucose and β-hydroxybuty (notice).pdf

    PDF document

    1.9 MB

Award criteria0

No procedure-level award criteria recorded.

Participants0

No participants recorded for this notice.